Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist

OBJECTIVE: The aim was to evaluate the cost-effectiveness of Crohn’s disease (CD) treatment with vedolizumab and ustekinumab after failure of therapy with tumor necrosis factor-α antagonists (anti-TNFs). METHODS: The Markov model incorporated the lifetime horizon, synthesis-based estimates of biolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Holko, Przemysław, Kawalec, Paweł, Pilc, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999163/
https://www.ncbi.nlm.nih.gov/pubmed/29667146
http://dx.doi.org/10.1007/s40273-018-0653-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999163/
https://www.ncbi.nlm.nih.gov/pubmed/29667146
http://dx.doi.org/10.1007/s40273-018-0653-2

Ejemplares similares